LAUSANNE, Switzerland, July 14, 2011 /PRNewswire/ —
Debiopharm Group™ (Debiopharm), a Swiss-based global
biopharmaceutical group of companies with a focus on the
development of innovative therapies, primarily in oncology, has
appointed a number of management figures to key positions, which
will help ensure the perennial success of the group over the long
term.
Although Debiopharm is a private company, it is committed to
ensure the same level of financial rigor and corporate governance
as companies listed on the stock market. It is for this reason that
Debiopharm has created a Strategy Committee, which will adopt
recommendations in respect of the overall direction of the group,
and a Development Committee, which will be tasked with optimising
the development stages of Debiopharm’s products. Dr Kamel Besseghir, who joined Debiopharm in
1995 and has been successfully heading Debiopharm S.A. as CEO since
2006, will chair both committees, starting January 1, 2012.
From that same date he will be succeeded as CEO of Debiopharm
S.A. by Dr Bertrand Ducrey, currently CEO of Debio R.P. (Martigny).
Bertrand Ducrey has a Ph.D. in Pharmaceutical Sciences and was
appointed general manager of Debio R.P. in 2004 before being
appointed CEO in 2006. Under Dr Ducrey’s leadership, Debio R.P.’s
achievements have significantly contributed to the success of
Debiopharm Group™.
Dr Ducrey’s current responsibilities as chief executive at Debio
R.P. will be taken over by Dr Cédric Sager, who will be
promoted to the position of CEO effective January 1, 2012. Dr Sager
joined Debio R.P. after having obtained his Ph.D. in Peptide
Chemistry in 2001. He held various positions within the company
before being appointed Manufacturing Director in 2004 and has
assisted the CEO with various responsibilities since 2007.
We thank our three colleagues for what they have achieved to
date and we wish them
‘/>”/>
